The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.

Andrew  Spencer

Honoraria - BMS; Janssen-Cilag

Consulting or Advisory Role - BMS; Janssen-Cilag

Speakers' Bureau - Janssen-Cilag

Research Funding - Janssen-Cilag

Philippe  Moreau

Honoraria - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; oncopeptides; Sanofi

Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen; oncopeptides; Sanofi

Maria-Victoria  Mateos

Honoraria - Abbvie/Genentech; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Sanofi; Takeda

Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Pfizer; Regeneron; Roche/Genentech; Takeda

Hartmut  Goldschmidt

Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Chugai Pharma; GlaxoSmithKline; Janssen-Cilag; Novartis; Sanofi

Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi (Inst); Takeda (Inst)

Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma Europe (Inst); Incyte (Inst); Janssen (Inst); Molecular Partners (Inst); MSD (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst)

Travel, Accommodations, Expenses - Janssen-Cilag; Sanofi

Other Relationship - Amgen (Inst); Celgene/Bristol-Myers Squibb (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Sanofi (Inst)

Kenshi  Suzuki

Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Novartis; Ono Pharmaceutical; Sanofi; Takeda

Consulting or Advisory Role - Amgen; Celgene; Janssen; Takeda

Research Funding - Bristol-Myers Squibb; Celgene

Mark-David  Levin

Honoraria - AbbVie; Celgene; Janssen; Takeda

Travel, Accommodations, Expenses - Janssen; Takeda

Pieter  Sonneveld

Consulting or Advisory Role - Amgen; CARsgen Therapeutics; Celgene; Janssen; Karyopharm Therapeutics

Research Funding - Amgen (Inst); BMS (Inst); Janssen (Inst); Skyline Diagnostics (Inst)

Sung-Soo  Yoon

Honoraria - Novartis

Consulting or Advisory Role - Amgen; Celgene/Jazz; Janssen; Takeda

Research Funding - Kyowa Kirin; Roche/Genentech; Yuhan

Saad Zafar  Usmani

Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb/Celgene; Celgene; Genentech; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Merck; Oncopeptides; Seagen; Skyline Diagnostics; Takeda

Speakers' Bureau - Amgen; Bristol-Myers Squibb/Celgene; Janssen Oncology; Sanofi; Takeda

Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Merck; Pharmacyclics; Sanofi; Seagen; Skyline Diagnostics

Katja  Weisel

Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Amgen (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene (Inst); Celgene; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline (Inst); Janssen (Inst); Janssen-Cilag; Karyopharm Therapeutics; Novartis; Oncopeptides; Pfizer; Roche; Sanofi; Sanofi (Inst); Takeda

Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Oncopeptides; Roche; Sanofi; Takeda

Research Funding - Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Takeda

Donna Ellen  Reece

Honoraria - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Takeda

Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Celgene; Janssen; Karyopharm Therapeutics

Research Funding - Bristol-Myers Squibb/Celgene (Inst); Janssen (Inst); Millennium (Inst); Takeda (Inst)

Expert Testimony - Bristol-Myers Squibb/Celgene; Janssen

Other Relationship - Canadian Myeloma Research Network

Tahamtan  Ahmadi

Employment - Genmab

Leadership - Genmab

Stock and Other Ownership Interests  - Genmab

Huiling  Pei

Employment - Janssen

Stock and Other Ownership Interests  - Janssen

Wendy  Garvin Mayo

Employment - Janssen

Xue  Gai

Employment - Janssen Research & Development

Stock and Other Ownership Interests  - Janssen Research & Development

Travel, Accommodations, Expenses - Janssen Research & Development

Jodi  Carey

Employment - Janssen Research & Development

Stock and Other Ownership Interests  - Johnson & Johnson

Robin L.  Carson

Employment - Janssen

Meletios A.  Dimopoulos

Honoraria - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Takeda

Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Takeda